孕激素用于ART卵巢刺激中垂体抑制的综合系统综述与荟萃分析
该综述系统评价了孕激素在ART卵巢刺激中抑制垂体分泌LH的作用,比较其与GnRH类似物的有效性、对卵母细胞和胚胎发育潜能及整倍体状态的影响以及成本效益。总体而言,孕激素与GnRH类似物的刺激时长、促性腺激素用量和获卵数相似,活产率、持续妊娠率和临床妊娠率也相似;但敏感性分析显示孕激素的促性腺激素用量显著低于长方案GnRH激动剂,而显著高于短方案GnRH激动剂;孕激素组的临床妊娠率在PCOS女性和短方案GnRH激动剂比较中显著更高,但证据质量低。孕激素可用于不计划新鲜胚胎移植的女性。
要点
- 孕激素与GnRH类似物的刺激时长、促性腺激素用量和获卵数总体相似。
- 孕激素的促性腺激素用量显著低于长方案GnRH激动剂,但显著高于短方案GnRH激动剂。
- 孕激素方案需全胚冷冻和延迟移植,可能增加每活产成本。
核心结论
- 孕激素是有效抑制垂体LH分泌的选择,适用于不计划新鲜胚胎移植的女性。
- 孕激素与GnRH类似物的活产率、持续妊娠率和临床妊娠率总体相似。
- 孕激素方案的胚胎整倍体状态与常规刺激周期相似,产科和新生儿结局信息令人放心。
研究设计与样本
- 系统综述与荟萃分析,检索Cochrane CENTRAL、MEDLINE via PubMed、Web of Science和Scopus,检索时间从各数据库建库至2020年4月1日,仅纳入英文全文。
主要发现
- 孕激素与GnRH类似物的刺激时长、促性腺激素用量和获卵数总体相似。
- 孕激素的促性腺激素用量显著低于长方案GnRH激动剂(MD=-648,95%CI=-746至-550 IU),显著高于短方案GnRH激动剂(MD=433,95%CI=311至555 IU)。
- 孕激素与GnRH激动剂比较,PCOS女性(RR=1.27,95%CI=1.06至1.53)和短方案GnRH激动剂(RR=1.14,95%CI=1.02至1.28)的临床妊娠率显著更高,但证据质量低。
- 醋酸甲羟孕酮、地屈孕酮和微粒化孕酮之间的卵巢反应和妊娠结局相似。
- 孕激素方案胚胎的整倍体状态与常规刺激周期相似。
临床怎么用
- 孕激素可用于不计划新鲜胚胎移植的女性,如生育力保存、预期高反应者、植入前遗传学检测、卵母细胞捐赠和双刺激周期。
- 使用孕激素方案需全胚冷冻并延迟移植。
局限性
- 比较孕激素与GnRH激动剂的临床妊娠率证据质量低。
- 孕激素方案因全胚冷冻和延迟移植可能增加每活产成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progestins are capable of suppressing endogenous LH secretion from the pituitary. Progestins can be used orally and are less expensive than GnRH analogues. However, early endometrial exposure to progestin precludes a fresh embryo transfer (ET), but the advent of vitrification and increasing number of oocyte cryopreservation cycles allow more opportunities for using progestins for pituitary suppression. OBJECTIVE AND RATIONALE: This review summarizes: the mechanism of pituitary suppression by progestins; the effectiveness of progestins when compared with GnRH analogues and with each other; the effect of progestins on oocyte and embryo developmental potential and euploidy status; and the cost-effectiveness aspects of progestin primed stimulation. Future research priorities are also identified. SEARCH METHODS: The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE via PubMed, the Web of Science and Scopus were screened with a combination of keywords related to ART, progesterone, GnRH analogue and ovarian stimulation, in various combinations. The search period was from the date of inception of each database until 1 April 2020. Only full text papers published in English were included. OUTCOMES: Overall, the duration of stimulation, gonadotrophin consumption and oocyte yield were similar with progestins and GnRH analogues. However, sensitivity analyses suggested that progestins were associated with significantly lower gonadotrophin consumption than the long GnRH agonist protocol (mean difference (MD) = -648, 95% CI = -746 to -550 IU) and significantly higher gonadotrophin consumption than the short GnRH agonist protocol (MD = 433, 95% CI = 311 to 555 IU). Overall, live birth, ongoing and clinical pregnancy rates per ET were similar with progestins and GnRH analogues. However, when progestins were compared with GnRH agonists, sensitivity analyses including women with polycystic ovary syndrome (risk ratio (RR) = 1.27, 95% CI = 1.06 to 1.53) and short GnRH agonist protocols (RR = 1.14, 95% CI = 1.02 to 1.28) showed significantly higher clinical pregnancy rates with progestins. However, the quality of evidence is low. Studies comparing medroxyprogesterone acetate, dydrogesterone and micronized progesterone suggested similar ovarian response and pregnancy outcomes. The euploidy status of embryos from progestin primed cycles was similar to that of embryos from conventional stimulation cycles. Available information is reassuring regarding obstetric and neonatal outcomes with the use of progestins. Despite the lower cost of progestins than GnRH analogues, the mandatory cryopreservation of all embryos followed by a deferred transfer may increase cost per live birth with progestins as compared to an ART cycle culminating in a fresh ET. WIDER IMPLICATIONS: Progestins can present an effective option for women who do not contemplate a fresh ET, e.g. fertility preservation, anticipated hyper responders, preimplantation genetic testing, oocyte donors, double stimulation cycles.
引用
- Ata B, Capuzzo M, Turkgeldi E, et al. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses. Hum Reprod Update. 2021. PMID: 33016316. doi:10.1093/humupd/dmaa040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。